mitochondrial ribosomal protein L50 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored MRPL50P2 profile across patient tissues and cancer cell-line models. MRPL50P2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in SARC. Among the 18 cancer types available for tumor–normal comparison, MRPL50P2 is differentially expressed in 2, with the highest sampling consensus in THCA. Additionally, MRPL50P2 RNA expression shows 10,560 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight SARC, THCA, and HNSC as cancer lineages where MRPL50P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPL50P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPL50P2 survival associations across molecular data types. MRPL50P2 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPL50P2 RNA expression–survival associations across cancer types. High MRPL50P2 expression shows unfavorable associations in ACC, UCEC and UVM, but favorable associations in SARC, COAD and STAD. The SARC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .007). Together, the overview and detailed table identify SARC as the clearest survival context for MRPL50P2 RNA expression.
This table summarizes MRPL50P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MRPL50P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPL50P2 shows lower tumor expression in THCA and STAD. The THCA box plot shows higher MRPL50P2 RNA expression in normal versus tumor tissue (log2 FC = −0.052, t-test p = .012).
This table shows molecular features associated with MRPL50P2 in patient tissues and cancer cell lines. In patient samples, MRPL50P2 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
